Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

• Published in: European heart journal Vol. 27; no. 10; pp. 1166 - 1173
• Main Authors: Jernberg, Tomas, Payne, Christopher D., Winters, Kenneth J., Darstein, Christelle, Brandt, John T., Jakubowski, Joseph A., Naganuma, Hideo, Siegbahn, Agneta, Wallentin, Lars
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 01.05.2006; Oxford Publishing Limited (England)
• Subjects: Adult; Aged; Aspirin - administration & dosage; Aspirin - adverse effects; Biological and medical sciences; Cardiology. Vascular system; Coronary Artery Disease - drug therapy; Coronary heart disease; Drug Therapy, Combination; Female; Heart; Humans; Male; Medical sciences; MEDICIN; MEDICINE; Middle Aged; Piperazines - administration & dosage; Piperazines - adverse effects; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - adverse effects; Prasugrel Hydrochloride; Thiophenes - administration & dosage; Thiophenes - adverse effects; Ticlopidine - administration & dosage; Ticlopidine - adverse effects; Ticlopidine - analogs & derivatives; Human; Rate; CS-747; Cardiovascular disease; Thienopyridine; Acetylsalicylic acid; Coronary heart disease; Phlebology; Aggregation; Prasugrel; Platelet; Treatment; Trials; Clopidogrel; Circulatory system; Inhibition; Cardiology; Platelets; Comparative study; Responder

This study was designed to compare the degree of inhibition of platelet aggregation (IPA) of prasugrel with that of clopidogrel in stable aspirin-treated patients with coronary artery disease (CAD). Subjects (n=101) were randomly assigned to the following loading dose (LD) (day 1)/maintenance dose (...